Ionis Pharmaceuticals, Inc. - Common Stock (NQ:IONS)

Ionis's $1.9 billion cash pile buys time, but it is still to be seen whether patient switches to DAWNZERA can offset a slower TRYNGOLZA launch.

Ionis: 3 Key Takeaways for Long-Term Investors ↗

November 09, 2026

Performance

52-Week Range 67.5% below 52-week high

28.19

27.7552W Low 86.7452W High

1 Week 32.6% below 1-week high

27.751W Low 41.831W High

Ionis Pharmaceuticals, Inc. - Common Stock (IONS) traded between $27.75 and $86.74 over the past 52 weeks and last traded at $28.19, 67.5% below its 52-week high. Over the past week it ranged between $27.75 and $41.83.

Past 12 Months

-30.3%

-35.4%

-50.5%

-62.6%

-64.6%

-59.5%

1W -$12.23

1M -$15.48

3M -$28.75

6M -$47.19

YTD -$51.48

1Y -$41.35

IONS was -59.5% over the past year, -62.6% over six months, -64.6% year to date, -30.3% in the last week.

12 Months vs Market

IONS

-59.5%

DIA

+10.1%

SPY

+10.0%

QQQ

+8.3%

IWM

+15.0%

Over the past 12 months IONS returned -59.5% versus DIA (Dow) +10.1%, SPY (S&P 500) +10.0%, QQQ (Nasdaq 100) +8.3% and IWM (Russell 2000) +15.0%.

Volume & Liquidity 2.98× 3-mo avg

Today 10,690,725 3-mo avg 3.6M

7.4M

3.9M

3.6M

3.2M

YTD

2.8M

IONS most recently traded 10,690,725 shares against a 3-month average daily volume of 3.6M.

More News

Ionis (IONS) Q3 2026 Earnings Call Transcript ↗

November 09, 2026

Ionis Pharmaceuticals (IONS) Shares Drop Following Sharp Reduction in TRYNGOLZA Sales Forecast – Kehoe Law Firm, P.C. Investigating

What Ionis Pharmaceuticals (IONS) Said on Its Q3 Earnings Call ↗

November 09, 2026

Via MarketBeat

US Gap-Up and Gap-Down Movers for the Nov. 9, 2026 Session ↗

November 09, 2026

Via Chartmill

November 09, 2026

From Kehoe Law Firm

Via GlobeNewswire

Premarket Movers on Nov. 9, 2026: Small-Cap Gainers and Losers ↗

November 09, 2026

Via Chartmill

Ionis reports third quarter 2026 financial results and highlights progress on key programs

November 09, 2026

Ionis to hold third quarter 2026 financial results webcast

November 02, 2026

Ionis partner Roche announces new Phase 3 data showing sefaxersen significantly reduced proteinuria in people with IgA nephropathy (IgAN)

October 23, 2026

Ionis ranked #1 on Science’s Top Employers list

October 22, 2026

Alnylam Is Now Solidly Profitable. Why Are Investors Treating It Like a Broken Biotech? ↗

October 21, 2026

Ionis partner GSK announces Hibsago (bepirovirsen) approved in the U.S. for the treatment of chronic hepatitis B (CHB)

October 20, 2026

TRYNGOLZA® (olezarsen) recommended for approval in the EU by CHMP for severe hypertriglyceridemia (sHTG)

October 16, 2026

Alnylam vs. Ionis: Here's the Better Bad-News Buy ↗

October 10, 2026

18 of 21 Analysts Still Think Alnylam Stock Is a Buy. Here's Why They're Right. ↗

September 28, 2026

Ionis announces positive interim data from partner Roche’s Phase 3 IMAgINATION study in IgA nephropathy (IgAN)

September 23, 2026

Ionis announces positive topline results from Phase 3 FUSION study of ulefnersen marking significant milestone in advancing first potential disease modifying treatment for FUS-ALS

September 22, 2026

Investors Dumped Ionis Pharmaceuticals Stock -- But Wall Street Hasn't Budged From Its Bullish Outlook ↗

September 20, 2026

Novartis Just Shook Up a Multibillion-Dollar Drug Race. What It Means for Eli Lilly Stock. ↗

Ionis Pharmaceuticals Eyes TRYNGOLZA Growth as Pipeline Faces Cardio Setbacks ↗

September 19, 2026

Via MarketBeat

September 14, 2026

Cathie Wood Is Loading Up on Ionis Pharmaceuticals (IONS) Stock. Here's the Bet She's Making. ↗

September 09, 2026

Ionis partner Novartis announces Lp(a)HORIZON Phase 3 topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD)

Stay updated with the stocks that are on the move in today's after-hours session. ↗

September 04, 2026

Via Chartmill

September 04, 2026